Vertex seeks to mobilise Sh5 billion for the Bond Fund through the issuance of 50 million units, and a further Sh5 billion ...

Pharma Vertex, CRISPR's gene-editing therapy Casgevy wins early FDA nod to treat beta thalassemia By Kevin Dunleavy Jan 16, 2024 3:40pm CRISPR Vertex Pharmaceuticals FDA Casgevy (exa-cel) ...

Vertex Announces FDA Clearance of Investigational New Drug Application for VX-264, a Novel Encapsulated Cell Therapy for the Treatment of Type 1 Diabetes – Vertex to initiate a Phase 1/2 ...

VX-264 and zimislecel came from Vertex’s 2019 acquisition of privately held Semma Therapeutics. The $950 million deal established Vertex’s presence in type 1 diabetes therapy R&D.

Vertex said all 12 achieved levels of blood glucose in the range recommended by the American Diabetes Association (ADA). Type 1 diabetes treatment requires blood glucose monitoring and frequent or ...

Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today provided updates on its Phase 1/2 clinical trial of VX-880, an investigational stem cell-deri ...